fulvestrant has been researched along with medroxyprogesterone acetate in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Duckles, SP; Krause, DN; McNeill, AM; Stanczyk, FZ; Zhang, C | 1 |
| Cano, A; García-Martínez, MC; Hermenegildo, C; Tarín, JJ | 1 |
| Gorbunova, VA; Howell, A; Lichinitser, MR; Pienkowski, T; Robertson, JF; Watanabe, T | 1 |
| Cheung, KL; Owers, R; Robertson, JF | 1 |
| Cahill, MA; Fehm, T; Mueck, AO; Neubauer, H; Ruan, X; Seeger, H; Tong, X; Yang, Y | 1 |
| Stanczyk, FZ | 1 |
| Giulianelli, S; Gutkind, JS; Helguero, LA; Lamb, CA; Lanari, C; Martins, R; Molinolo, AA; Soldati, R; Vanzulli, SI; Vaqué, JP; Wargon, V; Zeitlin, E | 1 |
| Giulianelli, S; Gutkind, JS; Helguero, L; Lamb, C; Lanari, C; Martins, R; Molinolo, AA; Soldati, R; Vanzulli, SI; Vaqué, JP; Wargon, V; Zeitlin, E | 1 |
| Iwase, H; Yamamoto, Y | 1 |
| Abraham, T; Arian, SE; Bartels, CB; Cayton, KC; Chuong, FS; Holthouser, K; Segars, JH | 1 |
2 review(s) available for fulvestrant and medroxyprogesterone acetate
| Article | Year |
|---|---|
Clinical benefit of sequential use of endocrine therapies for metastatic breast cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Neoplasm Metastasis; Ovariectomy; Postmenopause; Premenopause; Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen | 2015 |
An Evidence-based Approach to the Medical Management of Fibroids: A Systematic Review.
Topics: Androgens; Aromatase Inhibitors; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Curcumin; Delayed-Action Preparations; Drugs, Chinese Herbal; Estradiol; Estrenes; Estrogen Receptor Antagonists; Evidence-Based Medicine; Female; Fulvestrant; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Intrauterine Devices, Medicated; Leiomyoma; Levonorgestrel; Medroxyprogesterone Acetate; Mifepristone; Neoadjuvant Therapy; Norpregnadienes; Oximes; Plant Extracts; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tea; Uterine Myomectomy; Uterine Neoplasms; Vitamin D; Vitamins | 2016 |
1 trial(s) available for fulvestrant and medroxyprogesterone acetate
| Article | Year |
|---|---|
Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Postmenopause; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Tamoxifen; Treatment Outcome | 2006 |
8 other study(ies) available for fulvestrant and medroxyprogesterone acetate
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone.
Topics: Animals; Blood Vessels; Body Weight; Brain; Dose-Response Relationship, Drug; Drug Implants; Enzyme Activation; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Fulvestrant; In Vitro Techniques; Medroxyprogesterone Acetate; Models, Animal; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Organ Size; Ovariectomy; Progesterone; Rats; Rats, Inbred F344; Receptors, Estrogen; Tamoxifen; Uterus | 2002 |
Estradiol reduces F2alpha-isoprostane production in cultured human endothelial cells.
Topics: Cells, Cultured; Culture Media, Conditioned; Dose-Response Relationship, Drug; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Infant, Newborn; Isoprostanes; Male; Medroxyprogesterone Acetate; Piperidines; Progesterone; Progesterone Congeners; Umbilical Veins | 2002 |
Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Neoplasm Metastasis; Postmenopause; Retrospective Studies; Salvage Therapy; Tamoxifen; Treatment Outcome | 2005 |
The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Proliferation; Contraceptive Agents, Female; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Membrane Proteins; Receptors, Progesterone | 2011 |
Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1?
Topics: Breast Neoplasms; Contraceptive Agents, Female; Estradiol; Female; Fulvestrant; Humans; Medroxyprogesterone Acetate; Membrane Proteins; Receptors, Progesterone | 2011 |
Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
Topics: Animals; Breast Neoplasms; Cell Growth Processes; Cell Nucleus; Cyclin D1; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Humans; Mammary Neoplasms, Experimental; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Promoter Regions, Genetic; Receptors, Progesterone | 2012 |
[The role of estrogen receptor alpha in breast cancer cell proliferation mediated by progestins].
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Cell Proliferation; Chromatin Immunoprecipitation; Cyclin D1; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Genes, myc; Humans; Mammary Neoplasms, Experimental; Medroxyprogesterone Acetate; Murinae; Progestins; Receptors, Progesterone; Transcription, Genetic | 2012 |